Biotech entity
The clearest coverage concentration is pharma: 14 of 19 stories, with the rest divided among 3 other categories. Each story carries 5.2 original sources on average, compared with 3.5 for the broader beat in this window. Pfizer is most often covered alongside GSK, which appears in 7 of these 19 stories.
Last mentioned: 6d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 10 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 14 of 19 stories, with the rest divided among 3 other categories. Each story carries 5.2 original sources on average, compared with 3.5 for the broader beat in this window. Pfizer is most often covered alongside GSK, which appears in 7 of these 19 stories. Against the same-window beat baseline of 17% negative, this entity's 21% share is more negative. The 204-day window averages about 0.7 stories each week. The busiest single day carried 4. Their average consequence score of 6.1 sits level with the 6.1 recorded across the beat in that window. This profile follows 19 Biotech stories mentioning Pfizer across the period from February 22, 2026 to September 13, 2026.
Computed from the 19 stories linked to this entity, with beat comparisons drawn from all 757 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pfizer. Shared-story counts are live from our verified record — not editorial picks.
SDG Deadline
Target year for reducing neonatal mortality to 12 per 1,000 live births.
Potential Launch
Anticipated commercial availability following regulatory approval and CDC recommendation.
Regulatory Filing
Expected submission of Biologics License Application (BLA) to the FDA.
Pfizer-Valneva regulatory submission planned
Pfizer and Valneva announce they intend to file for approval of their Lyme disease vaccine candidate this spring, according to KFF Health News.
Efficacy Results
Trial data shows over 70% efficacy against Lyme disease in endemic regions.
Federal Injunction
A federal judge issues a temporary block on the administration's vaccine agenda, citing public health risks.
Mass Vaccination
UKHSA and NHS begin large-scale immunization drive using the Bexsero vaccine.
NHS Alert Issued
A formal alert is sent to NHS trusts and GP surgeries across England to prepare for increased vaccine demand.
Strain Confirmation
Laboratory results confirm Meningitis B as the causative agent; two fatalities reported.
UKHSA Briefing
Health chiefs describe the outbreak as 'explosive' and 'unprecedented' in national alerts.
Court Ruling
Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul.
Initial Reports
First cases of severe meningitis reported among students at the University of Kent.
Vaccine Mobilization
Emergency stocks of MenACWY and MenB vaccines are diverted to regional hubs.
Outbreak Confirmed
Public health officials confirm multiple linked cases and at least one fatality.
Initial Cases Reported
First reports of severe meningococcal symptoms emerge in student housing.
Surveillance Data Review
UKHSA identifies a rising trend in meningococcal strain activity among young adults.
Legal Challenge
The AAP and ACP file suit in Massachusetts federal court to block the changes.
Proposed Schedule Changes
The administration proposes sweeping changes to the national pediatric immunization schedule.
Policy Shift Initiated
RFK Jr. begins implementing a new agenda for federal vaccine oversight and safety reviews.
ACIP Restructuring
HHS replaces existing ACIP members with figures aligned with the administration's views.
The FDA has cleared updated COVID-19 vaccines from Pfizer, Moderna, and Novavax for 2026-27, targeting the XFG/Stratus strain. The decision resets the competitive landscape for seasonal vaccine makers.
Source: eastbaytimes.com · marinij.com
Pfizer and Valneva’s planned regulatory submission for a new Lyme disease vaccine enters a market haunted by the failure of LYMErix and amplified vaccine skepticism, challenging the blockbuster potential of a shot aimed at 476,000 annual U.S. cases.
Source: sun-sentinel.com · reporterherald.com
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
The Danish Medicines Agency’s real-world evidence analysis implicates drospirenone, desogestrel, gestodene, and others in meningioma development, reshaping the risk-benefit landscape for pharmaceutical manufacturers and future contraceptive R&D.
Source: 965therock.com · koolfmabilene.com
FDA scrutiny and shifting spending are forcing pharma marketers to adopt specialized platforms. These tools navigate privacy rules while enabling precise targeting, but they fragment the ad tech landscape.
Source: digiday.com · Digiday
Pfizer’s 2025 GLP-1 failure underscores a faltering pipeline just as generational patent cliffs approach. The 130% dividend payout ratio highlights the financial strain of recent R&D misses, challenging the biotech giant’s turnaround narrative.
Source: Reuben Gregg Brewer (us) · fool.com
Pfizer and Valneva have reported positive Phase 3 results for their Lyme disease vaccine candidate, VLA15, demonstrating an efficacy rate exceeding 70%. This development marks a significant milestone in addressing the growing public health threat of tick-borne illnesses, potentially offering the first preventative vaccine for the disease in over two decades.
A federal judge has issued a temporary injunction against Robert F. Kennedy Jr.’s proposed changes to national vaccine policy, citing potential risks to public health. The ruling provides a reprieve for pharmaceutical manufacturers and public health agencies while the legal merits of the administration's agenda are debated.
The Health Secretary has committed to an immediate expansion of meningitis vaccine supplies following a reported increase in cases to 27. This regulatory intervention aims to bolster public immunity and prevent a wider outbreak of the life-threatening infection.
The NHS has issued an urgent health alert across England as students begin receiving critical meningitis vaccinations to combat a seasonal rise in invasive meningococcal disease. Health officials are prioritizing first-year university students to prevent potential outbreaks in high-density campus environments.
Public health authorities have initiated an emergency vaccination campaign for students following a series of fatal meningitis cases in the UK. The drive aims to contain the spread of invasive meningococcal disease within high-risk educational environments through the rapid deployment of MenACWY and MenB vaccines.
Recent clinical findings indicate that patients with Mild Cognitive Impairment (MCI) and dementia face a significantly higher risk of developing new cardiovascular indications requiring anticoagulation therapy. This discovery underscores the critical link between cognitive decline and systemic vascular health in the aging population.
A new United Nations report reveals that approximately 4.9 million children under the age of five died in 2024, highlighting persistent gaps in global healthcare equity. While mortality rates have declined historically, the data underscores a critical need for expanded access to vaccines, antibiotics, and nutritional interventions.
UK health officials are responding to a severe Meningitis B outbreak at the University of Kent that has left two students dead and 11 others seriously ill. Described as "explosive" and "unprecedented," the cluster has triggered an urgent mass vaccination campaign and heightened surveillance across the region.
Health authorities have confirmed Meningitis B as the strain responsible for a recent outbreak resulting in two fatalities. The confirmation is expected to intensify the focus on regional vaccination coverage and the efficacy of current immunization protocols against emerging clusters.
A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws.
A nationwide recall has been issued for a wellness supplement after FDA testing revealed the presence of sildenafil, the active ingredient in Viagra. The undeclared pharmaceutical poses significant health risks, particularly to individuals with cardiovascular conditions taking nitrates.
Recent large-scale clinical studies are directly contradicting public health claims made by Robert F. Kennedy Jr. regarding the safety profiles of vaccines, acetaminophen, and antidepressants. These findings provide a critical scientific defense for pharmaceutical manufacturers facing increased regulatory scrutiny and litigation risks.
A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.
Source: kingstonthisweek.com · shorelinebeacon.com
Pfizer is linked from 19 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
